A 6-week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lurasidone (SM-13496) in Acutely Psychotic Subjects with Schizophrenia
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms JEWEL
- Sponsors Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals
- 23 Apr 2021 Primary endpoint (PANSS total Score) has been met, according to Results published in the Psychiatry and Clinical Neurosciences.
- 23 Apr 2021 Results published in the Psychiatry and Clinical Neurosciences.
- 25 Mar 2020 According to Sumitomo Dainippon Pharma, new drug application for LATUDA Tablets, an atypical antipsychotic agent for schizophrenia and bipolar depression, was approved in Japan on March 25